Venture Capital

With an $80M Series B led by Sky9 Capital, PhoenixAI is tackling the critical data bottleneck slowing enterprise AI, offering a new database for autonomous agents.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

With giants like BlackRock ranked alongside pioneers like Hyperliquid, Fortune's inaugural Crypto 100 signals a new era of legitimacy and institutional embrace.

A major financial outlook warns that geopolitical fragmentation, stubborn inflation, and a new AI arms race are creating a new reality for investors.

China's POP Culture Group reports a 141% revenue surge, fueled by digital. But as live events wane, can its IP-focused strategy win in a market of giants?

The asset manager's May report reveals $3.3B in net inflows, driven by a major target date fund win, underscoring its market resilience and leadership.

Micron's appointment of Dr. Alexis Black Björlin, an AI and cloud veteran, signals a strategic pivot to deepen its role in the future of intelligent infrastructure.

As Dubai's property market matures, IPS 2026 emerges as more than a showcase, creating a vital ecosystem where global capital meets next-gen urban innovation.

A tectonic shift is underway in how we get paid. Driven by AI and new laws, compensation is moving from a back-office task to a strategic business driver.

As AI costs soar and security risks mount, a new open-source microhypervisor aims to rebuild trust from the silicon up. Is this the architectural shift we need?

A new partnership brings advanced embryo screening to the Pacific, promising healthier babies while igniting a global race and fierce ethical debates.

With the hire of Dr. David Feygin, Outcome Capital signals a major bet on AI-driven advisory, reflecting a broader arms race in healthcare finance.

Nixxy Inc.'s radical pivot to a 1GW energy-first AI platform with Tachyon9 highlights a new industry truth: the AI race is now a power race.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

New research reveals Indigenous-led projects are not just a social good, but a critical economic engine for Canada's energy transition and resource economy.

Alumni Ventures, a top US firm, launches a London office and a new Global Alumni Syndicate, aiming to reshape VC access for international investors.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

As FACE Coalition’s Melamoon tour lands in Halifax, it's clear this is more than a pitch contest. It’s a strategic move to dismantle systemic barriers.

Horizon Growth's new CEO isn't just a management change; it's the final piece in a year-long transformation from a niche carbon firm to a diversified investor.